[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100597018":3},{"organization":4,"outcomesModule":7,"designInfo":14,"detailedDescription":20,"studyPopulation":13,"armGroups":21,"interventions":35,"overallOfficials":45,"centralContacts":49,"locations":54,"responsibleParty":72,"collaborators":13,"id":74,"slug":75,"hasResults":76,"nctId":77,"briefTitle":78,"officialTitle":78,"acronym":13,"eligibilityCriteria":79,"healthyVolunteers":76,"sex":80,"minAge":81,"maxAge":13,"enrollmentInfo":82,"targetDuration":13,"studyType":85,"phases":86,"briefSummary":88,"conditions":89,"keywords":13,"overallStatus":57,"whyStopped":13,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":100},{"fullName":5,"class":6},"M.D. Anderson Cancer Center","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":13},[9],{"measure":10,"description":11,"timeFrame":12},"Safety and Adverse Events (AEs)","Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0","Through study completion; an average of 1 year",null,{"allocation":15,"interventionModel":16,"interventionModelDescription":13,"primaryPurpose":17,"observationalModel":13,"timePerspective":13,"maskingInfo":18},"RANDOMIZED","SINGLE_GROUP","TREATMENT",{"masking":19,"maskingDescription":13,"whoMasked":13},"NONE","Primary Objective:\n\nTo determine whether SRS2 following surgery\u002FLITT for patients with recurrent previously irradiated brain metastases improves time to local recurrence compared to close surveillance following surgery\u002FLITT.\n\nTo summarize time to local recurrence for patients with recurrent previously irradiated brain metastases receiving SRS2 due to being ineligible for surgery\u002FLITT.\n\nSecondary Objectives:\n\nTo test if the effect of SRS2 versus surveillance after LITT or surgery in patients with recurrent previously irradiated brain metastases is associated with the type of surgical intervention.\n\nTo determine whether SRS2 versus close surveillance following surgery\u002FLITT for recurrent previously irradiated brain metastases improves distant brain metastasis-free survival, intracranial progression-free survival, overall progression-free survival, neurologic death rates, and\u002For overall survival.\n\nTo summarize distant brain metastasis-free survival, intracranial progression-free survival, overall progression-free survival, neurologic death rates, and\u002For overall survival for patients receiving SRS2 alone for recurrent, previously irradiated brain metastases.\n\nTo summarize patient-reported outcomes including neurocognitive symptoms, functional independence, and quality of life for patients who receive SRS2 for recurrent, previously irradiated brain metastases.\n\nTo summarize radionecrosis and adverse event rates for patients who receive SRS2 following surgery\u002FLITT for recurrent previously irradiated brain metastases.",[22,29,32],{"label":23,"type":24,"description":25,"interventionNames":26},"Eligible for surgery or LITT-Surveillance","EXPERIMENTAL","Patients will be randomized in a 1:1 manner to close surveillance versus SRS2.",[27,28],"Procedure: Surgery","Procedure: LITT",{"label":30,"type":24,"description":25,"interventionNames":31},"Eligible for surgery or LITT-SRS2",[27,28],{"label":33,"type":24,"description":25,"interventionNames":34},"Ineligible for surgery or LITT-SRS2",[27,28],[36,41],{"type":37,"name":38,"description":39,"armGroupLabels":40,"otherNames":13},"PROCEDURE","Surgery","Participants will initially undergo craniotomy and surgical resection of lesions or LITT",[30,23,33],{"type":37,"name":42,"description":43,"armGroupLabels":44,"otherNames":13},"LITT","Participants will undergo 4-core stereotactic biopsy and LITT by experienced neurosurgeons with specific expertise.",[30,23,33],[46],{"name":47,"affiliation":5,"role":48},"Subha Perni, MD","PRINCIPAL_INVESTIGATOR",[50],{"name":47,"role":51,"phone":52,"phoneExt":13,"email":53},"CONTACT","713-563-2543","sperni@mdanderson.org",[55],{"facility":56,"status":57,"city":58,"state":59,"zip":60,"country":61,"countryCode":62,"cosmosGeoPoint":63,"geoPoint":68,"contacts":69},"The University of Texas M. D. Anderson Cancer Center","RECRUITING","Houston","Texas","77030","United States","US",{"type":64,"coordinates":65},"Point",[66,67],-95.36327,29.76328,{"lat":67,"lon":66},[70,71],{"name":47,"role":51,"phone":52,"phoneExt":13,"email":53},{"name":47,"role":48,"phone":13,"phoneExt":13,"email":13},{"type":73,"investigatorFullName":13,"investigatorTitle":13,"investigatorAffiliation":13,"oldNameTitle":13,"oldOrganization":13},"SPONSOR","100597018","phase-2-laser-interstitial-thermal-therapy-litt-or-surgery-and-adjuvant-reirradiation-for-recurrent-brain-metastases-lasar-beam-100597018",false,"NCT07053033","Laser Interstitial Thermal Therapy (LITT) or Surgery and Adjuvant Reirradiation for Recurrent Brain Metastases (LaSAR BeaM)","Inclusion Criteria:\n\n* Ability to understand and the willingness to sign a written informed consent document.\n* Willingness to comply with all study procedures and availability for the duration of the study.\n* Age ≥18 years. Because no dosing or adverse event data are currently available on the use of SRS2, children are excluded from this study.\n* Karnofsky performance status ≥ 60.\n* Radiographic concern for progression of a solid tumor brain metastasis that has received prior stereotactic radiosurgery ≥ 3 months prior to study enrollment.\n* Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension as ≥5 mm with MRI scan.\n* Have active tumor on pathology from surgery\u002FLITT for this lesion.\n* Able to safely undergo MRI imaging.\n* Acceptable candidate for SRS2 per treating physician and multidisciplinary conference consensus.\n* Have no radiographic evidence of leptomeningeal disease on radiology report or neuro-radiologist review.\n* Patients with a prior or concurrent malignancy whose natural history or treatment does not interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.\n\nExclusion Criteria:\n\n* Patients with brain metastases from hematologic malignancies due to significant differences in radiosensitivity and treatment paradigms.\n* Patients with psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.\n* Pregnant women are excluded from this study because radiation has the potential for teratogenic or abortifacient effects. All female patients between the onset of menses and 55 years will receive a pregnancy test prior to SRS2 unless the patient presents with an applicable exclusionary factor which may be one of the following:\n* Postmenopausal (no menses in greater than or equal to 12 consecutive months).\n* History of hysterectomy or bilateral salpingo-oophorectomy.\n* Ovarian failure (Follicle Stimulating Hormone and Estradiol in menopausal range, who have received Whole Pelvic Radiation Therapy).\n* History of bilateral tubal ligation or another surgical sterilization procedure.","ALL","18 Years",{"count":83,"type":84},155,"ESTIMATED","INTERVENTIONAL",[87],"PHASE2","standard paradigm for management of patients who present with concern for recurrence of brain metastases following initial stereotactic radiosurgery (SRS).",[90],"Brain Metastases","2026-09-16",{"date":93,"type":94},"2026-09-18","ACTUAL",{"date":96,"type":94},"2026-01-01",{"date":98,"type":84},"2028-12-30",{"name":5,"class":6},1]